v3.26.1
Segments - Summary of Segment Profit (Detail) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Amounts Allocated To Segments [Abstract]        
Consolidated operating income (loss) $ (231) $ 455 $ 421 $ 975
Amounts Not Allocated To Segments [Abstract]        
Amortization 139 148 276 292
Other asset impairments, restructuring and other items 147 232 173 210
Intangible asset impairments 22 42 30 163
Legal settlements and loss contingencies 230 166 302 249
Other Unallocated Amounts 68 91 128 190
Revenues 4,142 4,176 8,124 8,067
R&D expenses 970 244 1,191 490
S&M expenses 717 654 1,413 1,276
G&A expenses 317 305 621 603
Segment profit (231) 455 421 975
Financial expenses, net 224 252 440 477
Consolidated income (loss) before income taxes (455) 203 (18) 497
United States [Member]        
Amounts Allocated To Segments [Abstract]        
Consolidated operating income (loss) (76) [1] 699 [2] 431 1,216
Amounts Not Allocated To Segments [Abstract]        
Revenues 1,702 1,786 3,236 3,322
Cost of Sales 499 574 995 1,097
R&D expenses 883 [3] 152 1,030 [3] 306
S&M expenses 294 250 593 493
G&A expenses 107 111 197 206
Other loss (income) (5)   (9) 3
Segment profit (76) [1] 699 [2] 431 1,216
Europe [Member]        
Amounts Allocated To Segments [Abstract]        
Consolidated operating income (loss) 367 [1] 364 [2] 768 693
Amounts Not Allocated To Segments [Abstract]        
Revenues 1,263 1,298 2,603 2,492
Cost of Sales 559 581 1,165 1,117
R&D expenses 52 [3] 59 97 [3] 120
S&M expenses 222 228 437 427
G&A expenses 66 66 139 135
Other loss (income) (3)   (3)  
Segment profit 367 [1] 364 [2] 768 693
International Markets [Member]        
Amounts Allocated To Segments [Abstract]        
Consolidated operating income (loss) 99 [1] 74 [2] 164 171
Amounts Not Allocated To Segments [Abstract]        
Revenues 550 495 1,074 1,077
Cost of Sales 266 251 547 556
R&D expenses 26 [3] 24 49 [3] 49
S&M expenses 128 114 245 232
G&A expenses 38 32 77 72
Other loss (income) (8) (1) (7) (2)
Segment profit 99 [1] 74 [2] 164 171
Corporate Segment [Member]        
Amounts Allocated To Segments [Abstract]        
Consolidated operating income (loss) 391 1,136 1,363 2,080
Amounts Not Allocated To Segments [Abstract]        
Segment profit 391 1,136 1,363 2,080
Other Segments [Member]        
Amounts Allocated To Segments [Abstract]        
Consolidated operating income (loss) (16) (3) (32) (1)
Amounts Not Allocated To Segments [Abstract]        
Segment profit $ (16) $ (3) $ (32) $ (1)
[1] Segment profit includes depreciation expenses of $36 million in the United States, $33 million in Europe and $17 million in International Markets.
[2] Segment profit includes depreciation expenses of $37 million in the United States, $31 million in Europe and $18 million in International Markets.
[3] Mainly related to the acquisition of Emalex and its primary asset ecopipam (EBS-101) in the United States segment. See ‘Emalex Biosciences’ included in note 2.